EBIT: Income before interest and taxes.
NRx Pharmaceuticals, Inc. (NRXP) had EBIT of $-4.74M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.07M |
|
$-1.43M |
|
$0.63M |
|
$0.44M |
|
$5.81M |
|
$-4.74M |
|
$3.30M |
|
$-1.44M |
|
$-1.44M |
|
$-1.44M |
|
$-1.44M |
|
$-1.44M |
|
$-1.44M |
|
|
EBIT |
$-4.74M |
$-4.58M |
|
32.33M |
|
32.33M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$7.36M |
|
$0.26M |
|
$4.54M |
|
$11.90M |
|
$25.18M |
|
-- |
|
$0.54M |
|
$25.72M |
|
$-13.82M |
|
$-16.49M |
|
$-13.82M |
|
33.47M |
|
| Cash Flow Statement Financials | |
$-4.29M |
|
$-0.21M |
|
$3.42M |
|
$7.80M |
|
$6.71M |
|
$-1.08M |
|
$0.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
40.92% |
|
-444.01% |
|
-444.01% |
|
-- |
|
-135.21% |
|
-133.90% |
|
$-4.29M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
5.90 |
|
15.25 |
|
10.45% |
|
8.76% |
|
-12.13% |
|
10.45% |
|
$-0.41 |
|
$-0.13 |
|
$-0.13 |
|